NHP.H — Lumiera Health Share Price
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | n/a | ||
Price to Tang. Book | n/a | ||
Price to Free Cashflow | n/a | ||
Price to Sales | n/a | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | n/a | ||
Return on Equity | n/a | ||
Operating Margin | -336.98% |
Financial Summary
Year End 30th Nov | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | n/a | n/a | n/a | 0.43 | 0.63 | n/a | n/a | 46.91% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Lumiera Health Inc. is a Canada-based natural health products company. The principal business of the Company is that of selling natural and homeopathic products. The Company specializes in the development and commercialization of evidence-based botanical products for the healthcare industry. The Company sells both oral and topical botanical agents to help manage unmet medical needs through its Holizen Laboratories division. It is also developing and commercializing a portfolio of innovative solutions in high growth categories such as sleep-aids and pain management. Its product's portfolio categories such as topical pain relief, sleep, skin care, women's health, & infections. The Company’s products and brands include Holizen, Awaye pain relief cream and Bazzzics. The Holizen portfolio has over 20 products that cover a range of therapeutic needs, including cardiovascular health; stress relief; bones, joints & muscle mobility; energy and immunity.
Directors
- Kevin Cole NEC
- Carlos Ponce CEO
- Simon Castonguay CFO
- Richard Giguere VPR
- Andre Rancourt DRC
- Marie Belanger IND
- Louis Doyle IND
- Nathalie Nasseri IND
- Frank Palantoni IND
- Michel Timperio IND
- Bertrand Venne IND
- Last Annual
- November 30th, 2022
- Last Interim
- August 31st, 2023
- Incorporated
- February 6th, 2013
- Public Since
- November 14th, 2013
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- TSX Venture Exchange
- Shares in Issue
- 169,965,217
- Address
- 4500 Blvd. Kimber, SAINT-HUBERT, J3Y 8K5
- Web
- https://www.lumiera.ca/
- Phone
- +1 4509262442
- Auditors
- Richter LLP
Upcoming Events for NHP.H
Similar to NHP.H
Aequus Pharmaceuticals
TSX Venture Exchange
Avricore Health
TSX Venture Exchange
Biosyent
TSX Venture Exchange
Cytophage Technologies
TSX Venture Exchange
Decibel Cannabis
TSX Venture Exchange
FAQ
As of Today at 21:51 UTC, shares in Lumiera Health are trading at CA$0.01. This share price information is delayed by 15 minutes.
Shares in Lumiera Health last closed at CA$0.01 and the price had moved by -66.67% over the past 365 days. In terms of relative price strength the Lumiera Health share price has underperformed the Toronto Stock Exchange 300 Composite Index by -68.68% over the past year.
There is no consensus recommendation for this security.
Find out moreLumiera Health does not currently pay a dividend.
Lumiera Health does not currently pay a dividend.
Lumiera Health does not currently pay a dividend.
To buy shares in Lumiera Health you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.01, shares in Lumiera Health had a market capitalisation of .
Here are the trading details for Lumiera Health:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: NHP
Based on an overall assessment of its quality, value and momentum Lumiera Health is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Lumiera Health. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -77.6%.
As of the last closing price of CA$0.01, shares in Lumiera Health were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Lumiera Health PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Lumiera Health's management team is headed by:
- Kevin Cole - NEC
- Carlos Ponce - CEO
- Simon Castonguay - CFO
- Richard Giguere - VPR
- Andre Rancourt - DRC
- Marie Belanger - IND
- Louis Doyle - IND
- Nathalie Nasseri - IND
- Frank Palantoni - IND
- Michel Timperio - IND
- Bertrand Venne - IND